Nicotinamide as an Early Alzheimer's Disease Treatment
Status:
Recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test whether nicotinamide, also known as vitamin B3
or niacinamide, taken in high doses, can reduce phosphorylation of tau (the protein that
accumulates in neurofibrillary tangles) in people with Mild Cognitive Impairment or mild
Alzheimer's disease (AD) dementia.